Vivekananda Budamagunta, PhD.
University of Florida
H-index: 9
North America-United States
Top articles of Vivekananda Budamagunta, PhD.
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Senolytic treatment alleviates doxorubicin‐induced chemobrain | Aging Cell | Vivekananda Budamagunta Ashok Kumar Asha Rani Sahana Manohar Sindhu Yang Yang | 2024/2 |
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice | Cell Death Discovery | Sajid Khan Patrick Kellish Nick Connis Dinesh Thummuri Janet Wiegand | 2023/1/2 |
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies | Sajid Khan Vivekananda Budamagunta Daohong Zhou | 2023/1/1 | |
Effect of peripheral cellular senescence on brain aging and cognitive decline | Aging Cell | Vivekananda Budamagunta Ashok Kumar Asha Rani Linda Bean Sahana Manohar‐Sindhu | 2023/5 |
Nanovesicle and extracellular polymeric substance synthesis from the remediation of heavy metal ions from soil | Environmental research | Vivekananda Budamagunta Nowsheen Shameem Sivaraj Irusappan Javid A Parray Merin Thomas | 2023/2/15 |
A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers | Cancer Research | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/6/15 |
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers | Journal of Hematology & Oncology | Sajid Khan Janet Wiegand Peiyi Zhang Wanyi Hu Dinesh Thummuri | 2022/3/9 |
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 | Molecular cancer therapeutics | Dinesh Thummuri Sajid Khan Patrick W Underwood Peiyi Zhang Janet Wiegand | 2022/1/1 |
Cellular senescence in lymphoid organs and immunosenescence | Vivekananda Budamagunta Thomas C Foster Daohong Zhou | 2021/8/8 | |
Senescence-associated hyper-activation to inflammatory stimuli in vitro | Aging (Albany NY) | Vivekananda Budamagunta Sahana Manohar-Sindhu Yang Yang Yonghan He Dmitry O Traktuev | 2021/8/8 |
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity | Aging cell | Yonghan He Wen Li Dongwen Lv Xin Zhang Xuan Zhang | 2020/3 |
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas | Journal of hematology & oncology | Yonghan He Raphael Koch Vivekananda Budamagunta Peiyi Zhang Xuan Zhang | 2020/12 |
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines | European journal of medicinal chemistry | Xuan Zhang Yonghan He Peiyi Zhang Vivekananda Budamagunta Dongwen Lv | 2020/8/1 |
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity | Nature communications | Yonghan He Xuan Zhang Jianhui Chang Ha-Neui Kim Peiyi Zhang | 2020/4/24 |
Co-Authors
